Curated News
By: NewsRamp Editorial Staff
May 12, 2025
SeaStar Medical's QUELIMMUNE Therapy Making Waves in Pediatric AKI Treatment
TLDR
- SeaStar Medical aims to revolutionize pediatric AKI treatment with QUELIMMUNE, giving them a competitive advantage in the healthcare industry.
- QUELIMMUNE therapy is approved by the FDA and connected to existing hemodialysis systems, providing a methodical approach to treating pediatric AKI.
- QUELIMMUNE offers life-saving results, reduces healthcare costs, and improves patient outcomes, making the world a better place for pediatric AKI patients and their families.
- SeaStar Medical's innovative therapy, QUELIMMUNE, shows promising results with no device-related infections and a 77% survival rate, offering an interesting solution to pediatric AKI.
Impact - Why it Matters
This news matters as SeaStar Medical's innovative approach to treating pediatric and adult AKI could potentially save many lives and reduce healthcare costs. By addressing a critical medical need often overlooked, SeaStar is leading the way in providing life-saving solutions for patients facing organ failure and associated risks.
Summary
SeaStar Medical is revolutionizing the treatment of pediatric acute kidney injury (AKI), a condition affecting 4,000 U.S. children annually with high mortality rates and long ICU stays. The company's newly approved product, QUELIMMUNE, aims to address this critical need by providing a therapeutic solution that has shown significant clinical benefits.
The FDA-approved QUELIMMUNE therapy has demonstrated a 77% survival rate in pediatric AKI patients with no dialysis dependency after 60 days. SeaStar is also expanding its focus to treat adult AKI, with a trial underway to evaluate the safety and efficacy of its second proprietary therapy in 200 adult patients.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, SeaStar Medical's QUELIMMUNE Therapy Making Waves in Pediatric AKI Treatment
